Britain stages a float fightback

Among the biggest dangers for the post-Brexit City is that too many brilliant British start-ups in biotechnology, financial innovation and online consumer enterprises head to New York in search of rocket-powered valuations. Where the money goes, too often intellectual property follows. It is worrying that Oxford-based Immunocore, pioneer of an immunology treatment for cancer, has […]

Continue Reading